Sean Harrop, Pietro R Di Ciaccio, N. W. Doo, T. Cochrane, B. Campbell, N. Hamad, M. Dickinson, C. van der Weyden, H. Prince
{"title":"The gamma delta lymphomas: an Australian multi-centre case series","authors":"Sean Harrop, Pietro R Di Ciaccio, N. W. Doo, T. Cochrane, B. Campbell, N. Hamad, M. Dickinson, C. van der Weyden, H. Prince","doi":"10.21037/aol-21-41","DOIUrl":"https://doi.org/10.21037/aol-21-41","url":null,"abstract":"","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78515343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The diversity challenges in follicular lymphoma","authors":"M. Roschewski, C. Casulo","doi":"10.21037/aol-2022-1","DOIUrl":"https://doi.org/10.21037/aol-2022-1","url":null,"abstract":"","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"72 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75673599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Complete response of relapsed adult T-cell lymphoma leukemia to a Bcl-2 inhibitor: a case report","authors":"A. Petrillo, M. Albitar, T. Feldman","doi":"10.21037/aol-21-23","DOIUrl":"https://doi.org/10.21037/aol-21-23","url":null,"abstract":"","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82034307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
: Follicular lymphoma (FL) is an indolent disease with a continuously remitting course. Despite improved treatment options, about 20% of patients suffer from early relapse and subsequent death. Several baseline clinical, histological and biological parameters have been identified as risk factors for adverse outcome, but they do not predict response to treatment and are currently not being used for risk adapted treatment strategies. In recent years, minimal residual (detectable) disease (MRD) detection has gained considerable interest as a post-treatment outcome predictor and a considerable amount of data has been generated in the field. MRD integrates preclinical risk factors and their influence on achievement of response, by dynamically monitoring the clearance of lymphoma cells during treatment early feedback on the efficacy of treatment for the individual patient can be achieved as well as the identification of adverse prognostic subgroups. Detectable MRD or kinetics of lymphoma regrowth after the end of treatment (EOT) identifies patients at risk of clinical relapse much earlier than imaging techniques. Therefore, MRD assessment allows a stratification for individualized treatment approaches early in the treatment course and might provide tailored treatment approaches in the future. This review will discuss major technical advances and significant clinical messages that have been derived from the application of MRD monitoring in clinical trials during the last decade. Furthermore, we discuss the prognostic role of combined metabolic response by 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET) and molecular MRD analysis at end of induction (EOI) as an endpoint and early read-out in clinical trials. 16
{"title":"Minimal residual disease in follicular lymphoma","authors":"C. Pott, D. Wellnitz, M. Ladetto","doi":"10.21037/aol-21-25","DOIUrl":"https://doi.org/10.21037/aol-21-25","url":null,"abstract":": Follicular lymphoma (FL) is an indolent disease with a continuously remitting course. Despite improved treatment options, about 20% of patients suffer from early relapse and subsequent death. Several baseline clinical, histological and biological parameters have been identified as risk factors for adverse outcome, but they do not predict response to treatment and are currently not being used for risk adapted treatment strategies. In recent years, minimal residual (detectable) disease (MRD) detection has gained considerable interest as a post-treatment outcome predictor and a considerable amount of data has been generated in the field. MRD integrates preclinical risk factors and their influence on achievement of response, by dynamically monitoring the clearance of lymphoma cells during treatment early feedback on the efficacy of treatment for the individual patient can be achieved as well as the identification of adverse prognostic subgroups. Detectable MRD or kinetics of lymphoma regrowth after the end of treatment (EOT) identifies patients at risk of clinical relapse much earlier than imaging techniques. Therefore, MRD assessment allows a stratification for individualized treatment approaches early in the treatment course and might provide tailored treatment approaches in the future. This review will discuss major technical advances and significant clinical messages that have been derived from the application of MRD monitoring in clinical trials during the last decade. Furthermore, we discuss the prognostic role of combined metabolic response by 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG-PET) and molecular MRD analysis at end of induction (EOI) as an endpoint and early read-out in clinical trials. 16","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"110 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81251627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Wiltshire, D. Kliman, J. Tan, H. Quach, A. Kalff, R. Cameron, G. Grigoriadis, H. Nandurkar
Primary effusion lymphoma (PEL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL) accounting for <1% of all cases of lymphoma in the general population. It manifests as malignant effusions within the body affecting the pleural, pericardial and peritoneal cavities. It is seen most commonly in individuals coinfected with the human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV8) and carries a poor prognosis with a median overall survival of approximately 6 months. Treatment options are challenging both from limited evidence in this area, as well as by patient suitability for therapy, as PEL often affects an elderly male population. For those patients with PEL fit for chemotherapy they often will receive a combination regimen, involving an anthracycline, which may not be suitable for some of the elderly population affected, especially those with a history of cardiac disease. In this report, we explored a completely novel approach and describe the only reported case of prolonged clinical remission through the use of daratumumab (an anti-CD38 antibody) as first line of therapy in an 85-year-old gentleman diagnosed with HIV-negative PEL with pericardial involvement. At the time of this report our patient has been in an ongoing clinical remission for over a year and continues on monthly daratumumab maintenance with a good quality of life and no adverse events from therapy.
{"title":"Daratumumab as first line therapy in primary effusion lymphoma: a case report","authors":"K. Wiltshire, D. Kliman, J. Tan, H. Quach, A. Kalff, R. Cameron, G. Grigoriadis, H. Nandurkar","doi":"10.21037/aol-21-26","DOIUrl":"https://doi.org/10.21037/aol-21-26","url":null,"abstract":"Primary effusion lymphoma (PEL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL) accounting for <1% of all cases of lymphoma in the general population. It manifests as malignant effusions within the body affecting the pleural, pericardial and peritoneal cavities. It is seen most commonly in individuals coinfected with the human immunodeficiency virus (HIV) and human herpesvirus-8 (HHV8) and carries a poor prognosis with a median overall survival of approximately 6 months. Treatment options are challenging both from limited evidence in this area, as well as by patient suitability for therapy, as PEL often affects an elderly male population. For those patients with PEL fit for chemotherapy they often will receive a combination regimen, involving an anthracycline, which may not be suitable for some of the elderly population affected, especially those with a history of cardiac disease. In this report, we explored a completely novel approach and describe the only reported case of prolonged clinical remission through the use of daratumumab (an anti-CD38 antibody) as first line of therapy in an 85-year-old gentleman diagnosed with HIV-negative PEL with pericardial involvement. At the time of this report our patient has been in an ongoing clinical remission for over a year and continues on monthly daratumumab maintenance with a good quality of life and no adverse events from therapy.","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83944902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Adoptive cellular immunotherapy for Epstein-Barr virus (EBV)-associated lymphoproliferative disease","authors":"B. Wistinghausen, H. Dave, C. Bollard","doi":"10.21037/aol-21-43","DOIUrl":"https://doi.org/10.21037/aol-21-43","url":null,"abstract":"","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88148177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Wästerlid, Shannon Murphy, D. Villa, T. El‐Galaly
{"title":"Diffuse large B-cell lymphoma among the elderly: a narrative review of current knowledge and future perspectives","authors":"T. Wästerlid, Shannon Murphy, D. Villa, T. El‐Galaly","doi":"10.21037/aol-22-2","DOIUrl":"https://doi.org/10.21037/aol-22-2","url":null,"abstract":"","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84649178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Primary diffuse large B-cell lymphoma of the central nervous system: molecular and biological features of neoplastic cells","authors":"F. Bertoni, M. Montesinos-Rongen","doi":"10.21037/aol-21-38","DOIUrl":"https://doi.org/10.21037/aol-21-38","url":null,"abstract":"","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79078364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignancy that arises in 2-5% of carriers of human T-cell lymphotropic virus type 1 (HTLV-1). The median overall survival of acute and lymphoma subtypes remains approximately 9–13 months and depressingly, with chemotherapy based approaches survival is largely unchanged in the ~40 years since it was first described. There is a clear and urgent need to conduct clinical trials of novel therapies in this disease. A high proviral load (PVL) (>4%, percentage of HTLV-1 infected mononuclear cells), male gender and smoking were previously the only major known risk factors for developing ATL, and so it has been difficult to advise patients about their individual risk of future ATL. Here, we describe the recent evidence that malignant disease does not occur randomly amongst all asymptomatic carriers but is more likely to arise in a subset of high PVL individuals with abnormally abundant clonal expansions of circulating HTLV-1 infected T-cells which typically express CD3dim+ CD4+ CD5-CD7CD25+ CCR4+ with monoclonal TCRVβ. These clones also typically harbour known ATL driver mutations such as PLCG1, PRKCB, CARD11, STAT3, VAV1, NOTCH1, IRF4, CCR4, CCR7, TP53 and CDKN2, and may be detectable 10 years prior to disease presentation providing an opportunity to identify at risk individuals prior to clinical ATL. We describe the current classification and clinical features of ATL, and the exciting work of the last few years that underpins our new understanding of the genetic and epigenetic landscape with implications for future therapy. Whilst current therapy for aggressive ATL remain largely ineffective, recent advances may allow for early identification of at-risk individuals, and for pre-emptive therapies, and hope for a new era of effective targeted biological agents.
{"title":"Adult T-cell leukemia/lymphoma—pathobiology and implications for modern clinical management","authors":"L. Cook, A. Rowan, C. Bangham","doi":"10.21037/AOL-21-6","DOIUrl":"https://doi.org/10.21037/AOL-21-6","url":null,"abstract":"Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignancy that arises in 2-5% of carriers of human T-cell lymphotropic virus type 1 (HTLV-1). The median overall survival of acute and lymphoma subtypes remains approximately 9–13 months and depressingly, with chemotherapy based approaches survival is largely unchanged in the ~40 years since it was first described. There is a clear and urgent need to conduct clinical trials of novel therapies in this disease. A high proviral load (PVL) (>4%, percentage of HTLV-1 infected mononuclear cells), male gender and smoking were previously the only major known risk factors for developing ATL, and so it has been difficult to advise patients about their individual risk of future ATL. Here, we describe the recent evidence that malignant disease does not occur randomly amongst all asymptomatic carriers but is more likely to arise in a subset of high PVL individuals with abnormally abundant clonal expansions of circulating HTLV-1 infected T-cells which typically express CD3dim+ CD4+ CD5-CD7CD25+ CCR4+ with monoclonal TCRVβ. These clones also typically harbour known ATL driver mutations such as PLCG1, PRKCB, CARD11, STAT3, VAV1, NOTCH1, IRF4, CCR4, CCR7, TP53 and CDKN2, and may be detectable 10 years prior to disease presentation providing an opportunity to identify at risk individuals prior to clinical ATL. We describe the current classification and clinical features of ATL, and the exciting work of the last few years that underpins our new understanding of the genetic and epigenetic landscape with implications for future therapy. Whilst current therapy for aggressive ATL remain largely ineffective, recent advances may allow for early identification of at-risk individuals, and for pre-emptive therapies, and hope for a new era of effective targeted biological agents.","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77210714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Kelly, T. Habermann, C. Bollard, K. Dunleavy, T. Gross, T. Henderson, A. LaCasce, C. Steidl
Adolescent and young adult (AYA) lymphoma is defined as lymphoma diagnosed in patients between 15 and 39 years of age. When compared to children and adults, AYAs have not seen the same improvement in survival over recent years, even with the introduction of novel agents and interventions. This survival gap is driven by multiple compounding factors, including unique disease biology, challenges with survivorship care, socioeconomic factors, and cancer care treatment setting, among others. There is no established standard of care for AYA lymphomas, and many clinical trials do not evaluate AYAs as a separate subgroup or include measures that are of particular importance to AYAs. The Lymphoma Research Foundation (LRF), the nation’s largest non-profit organization dedicated exclusively to lymphoma research and patient advocacy, hosted its inaugural AYA Consortium Meeting to discuss research findings that support the recognition of AYAs as a distinct group of lymphoma patients. Attendees, comprised of expert lymphoma researchers and clinicians, discussed unmet needs, gaps in data, and strategies for improving AYA care clinical and psychosocial outcomes. This report, which includes a summary of each presentation, aims to review recent findings in AYA lymphoma research and highlight potential areas for future study.
{"title":"Report from the Lymphoma Research Foundation Adolescent and Young Adult (AYA) Lymphoma Scientific Workshop, May 2019","authors":"K. Kelly, T. Habermann, C. Bollard, K. Dunleavy, T. Gross, T. Henderson, A. LaCasce, C. Steidl","doi":"10.21037/AOL-2020-02","DOIUrl":"https://doi.org/10.21037/AOL-2020-02","url":null,"abstract":"Adolescent and young adult (AYA) lymphoma is defined as lymphoma diagnosed in patients between 15 and 39 years of age. When compared to children and adults, AYAs have not seen the same improvement in survival over recent years, even with the introduction of novel agents and interventions. This survival gap is driven by multiple compounding factors, including unique disease biology, challenges with survivorship care, socioeconomic factors, and cancer care treatment setting, among others. There is no established standard of care for AYA lymphomas, and many clinical trials do not evaluate AYAs as a separate subgroup or include measures that are of particular importance to AYAs. The Lymphoma Research Foundation (LRF), the nation’s largest non-profit organization dedicated exclusively to lymphoma research and patient advocacy, hosted its inaugural AYA Consortium Meeting to discuss research findings that support the recognition of AYAs as a distinct group of lymphoma patients. Attendees, comprised of expert lymphoma researchers and clinicians, discussed unmet needs, gaps in data, and strategies for improving AYA care clinical and psychosocial outcomes. This report, which includes a summary of each presentation, aims to review recent findings in AYA lymphoma research and highlight potential areas for future study.","PeriodicalId":72224,"journal":{"name":"Annals of lymphoma","volume":"524 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80128638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：